Virtual Event
23 – 25 June 2026
Step into the next era of life sciences at The Future of Bio/Pharma Analysis 2026. This three-day virtual event opens with a deep dive into the critical pillars of QA/QC, exploring the modernisation of environmental monitoring for emerging modalities like cell and gene therapies, the shift toward sustainable, non-animal endotoxin testing and state-of-the-art contamination control strategies.
This will be followed by a regulatory strategy day that will tackle key issues for the biopharma sector, including the ongoing, evolving threat presented by nitrosamine impurities. Key trends in reference standards will also examined in detail as the sessions continue their focus on how to navigate regulatory change in the US and Europe.
The third and final day will spotlight all things digital to bridge the gap between traditional practices and the next generation of pharmaceutical excellence. To this end it will offer practical insights on artificial intelligence (AI), automation and digitalisation across the biopharma manufacturing value chain.
We invite you and your colleagues to join us for an immersive experience that bridges the gap between traditional practices and the next generation of pharmaceutical excellence.
More to Come: Our full programme is currently under development. Be sure to check back regularly as we announce new sessions.
Join us as we debate the future of pharmaceutical analysis
Join us for three days of learning, networking, and innovation in the bio / pharma industry
Business Development Director
+44 (0) 1959 581 827
[email protected]
Connect with Decision-Makers. Accelerate Your Pipeline.
As biopharma transitions into an “AI-Native” and “Next-Gen Modality” era, Equipment Manufacturers and CDMOs are the essential engines of this change. We offer various levels of partnership designed to align your brand with the industry’s most urgent priorities.
